Journal article
Recombinant activated factor VII for the treatment of life-threatening haemorrhage
Abstract
To describe the use of recombinant activated factor VII (rFVIIa) in patients with life-threatening haemorrhage. We report a case series of Australian patients with life-threatening haemorrhage who were treated with rFVIIa prior to August 2002 namely 21 patients, median age 45 years (range 22-79 years), 33% (seven of 21) female. The major causes for bleeding were multi-trauma, cardiac or vascular surgery, or orthoptic liver transplantation. In …
Authors
Eikelboom JW; Bird R; Blythe D; Coyle L; Gan E; Harvey M; Isbister J; Leahy M; McIlroy D; Rahimpanah F
Journal
Blood Coagulation & Fibrinolysis, Vol. 14, No. 8, pp. 713–717
Publisher
Wolters Kluwer
Publication Date
December 2003
DOI
10.1097/00001721-200312000-00004
ISSN
0957-5235